Molecular genetic alterations in adrenal and extra-adrenal pheochromocytomas and paragangliomas

Endocrine Pathology

Volumn 14, Issue 4, 2003, Pages 329-350

  Dannenberg, Hilde ^a   Komminoth, Paul ^b   Dinjens, Winand N M ^a   Speel, Ernst Jan M ^c   De Krijger, Ronald R ^a  

^a JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

^b Kantonsspital Baden   (Switzerland)

^c MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

CGH; Molecular pathogenesis; Paraganglioma; Pheochromocytoma; RET; SDH; VHL

Indexed keywords

BIOCHEMICAL MARKER; COMPLEMENTARY DNA; MYC PROTEIN; PROTEIN P53; PROTEIN RET; RAS PROTEIN; RETINOBLASTOMA PROTEIN; SUCCINATE DEHYDROGENASE; TELOMERASE;

ADRENAL TUMOR; CARCINOGENESIS; COMPARATIVE GENOMIC HYBRIDIZATION; CONFERENCE PAPER; DNA MICROARRAY; FAMILY HISTORY; GENE MUTATION; GENETIC PREDISPOSITION; GENOME ANALYSIS; HUMAN; MOLECULAR GENETICS; NEURAL CREST; NEUROENDOCRINE TUMOR; NEUROFIBROMATOSIS; NONHUMAN; PARAGANGLIOMA; PATHOGENESIS; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; SIPPLE SYNDROME; VON HIPPEL LINDAU DISEASE;

ADRENAL GLAND NEOPLASMS; ANIMALS; HIPPEL-LINDAU DISEASE; HUMANS; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2B; MUTATION; NEUROFIBROMATOSIS 1; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PARAGANGLIOMA; PHEOCHROMOCYTOMA; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-RET; RECEPTOR PROTEIN-TYROSINE KINASES; TUMOR MARKERS, BIOLOGICAL;

EID: 3142516125     PISSN: 10463976     EISSN: None     Source Type: Journal    
DOI: 10.1385/EP:14:4:329     Document Type: Conference Paper

References (203)

1. Glenner GG, Grimley PM. Tumors of the extra-adrenal paraganglion system (including chemoreceptors). Atlas of tumor pathology. Washington DC: Armed Forces Institute of Pathology, 1974.
2. Goldstein RE, O'Neill JA, Jr., Holcomb GW, 3rd, et al. Clinical experience over 48 years with pheochromocytoma. Ann Surg 229:755-764; discussion 764-756, 1999.
3. Mannelli M, Ianni L, Cilotti A, Conti A. Pheochromocytoma in Italy: a multicentric retrospective study. Eur J Endocrinol 141:619-624, 1999.
4. van Heerden JA, Roland CF, Carney JA, Sheps SG, Grant CS. Long-term evaluation following resection of apparently benign pheochromocytoma(s)/ paraganglioma(s). World J Surg 14:325-329, 1990.
5. Noshiro T, Shimizu K, Watanabe T, et al. Changes in clinical features and long-term prognosis in patients with pheochromocytoma. Am J Hypertens 13:35-43, 2000.
6. Favia G, Lumachi F, Polistina F, D'Amico DF. Pheochromocytoma, a rare cause of hypertension: long-term follow-up of 55 surgically treated patients. World J Surg 22:689-693; discussion 694, 1998.
7. Brunt LM, Lairmore TC, Doherty GM, Quasebarth MA, DeBenedetti M, Moley JF. Adrenalectomy for familial pheochromocytoma in the laparoscopic era. Ann Surg 235:713-720; discussion 720-711, 2002.
8. Neumann HP, Bausch B, McWhinney SR, et al. Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med 346:1459-1466, 2002.
9. Lack EE, Cubilla AL, Woodruff JM. Paragangliomas of the head and neck region. A pathologic study of tumors fro m 71 patients. Hum Pathol 10:191-218, 1979.
10. Batsakis JG. Chemodectomas of the head and neck. In: Batsakis JG, ed. Tumors of the head and neck. Clinical and pathological considerations. Baltimore, MD: Williams and Wilkins, 1976, pp. 280-288.
11. Lee JH, Barich F, Karnell LH, et al. National Cancer Data Base report on malignant paragangliomas of the head and neck. Cancer 94:730-737, 2002.
12. Drovdlic CM, Myers EN, Peters JA, et al. Proportion of heritable paraganglioma cases and associated clinical characteristics. Laryngoscope 111:1822-1827, 2001.
13. Baysal BE, Willett-Brozick JE, Lawrence EC, et al. Prevalence of SDHB, SDHC, and SDHD germline mutations in clinic patients with head and neck paragangliomas. J Med Genet 39:178-183, 2002.
14. Dannenberg H, Dinjens WN, Abbou M, et al. Frequent germ-line succinate dehydrogenase subunit D gene mutations in patients with apparently sporadic parasympathetic paraganglioma. Clin Cancer Res 8:2061-2066, 2002.
15. Taschner PE, Jansen JC, Baysal BE, et al. Nearly all hereditary paragangliomas in the Netherlands are caused by two founder mutations in the SDHD gene. Genes Chromosomes Cancer 31:274-281, 2001.
16. Saldana MJ, Salem LE, Travezan R. High altitude hypoxia and chemodectomas. Hum Pathol 4:251-263, 1973.
17. Nissenblatt MJ. Cyanotic heart disease: "low altitude" risk for carotid body tumor? Johns Hopkins Med J 142:18-22, 1978.
18. Lack EE, Perez-Atayde AR, Young JB. Carotid body hyperplasia in cystic fibrosis and cyanotic heart disease. A combined morphometric, ultrastructural, and biochemical study. Am J Pathol 119:301-314, 1985.
19. Le Douarin NM. The neural crest. Cambridge, UK: Cambridge University Press, 1982.
20. Komminoth P, de Krijger RR, Tischler AS. Paraganglia and the adrenal medulla. In: LiVolsi VA, Asa SL, eds. Endocrine pathology, Philadelphia: Churchill Livingstone, 2002, pp. 149-169.
21. McNichol AM. Differential diagnosis of pheochromocytomas and paragangliomas. Endocr Pathol 12:407-415, 2001.
22. Chetty R, Pillay P, Jaichand V. Cytokeratin expression in adrenal phaeochromocytomas and extra-adrenal paragangliomas. J Clin Pathol 51:477-478, 1998.
23. Fraga M, Garcia-Caballero T, Antunez J, Couce M, Beiras A, Forteza J. A comparative immunohistochemical study of phaeochromocytomas and paragangliomas. Histol Histopathol 8:429-436, 1993.
24. Sato T, Saito H, Yoshinaga K, Shibota Y, Sasano N. Concurrence of carotid body tumor and pheochromocytoma. Cancer 34:1787-1795, 1974.
25. Jensen JC, Choyke PL, Rosenfeld M, et al. A report of familial carotid body tumors and multiple extra-adrenal pheochromocytomas. J Urol 145:1040-1042, 1991.
26. Baysal BE. Hereditary paraganglioma targets diverse paraganglia. J Med Genet 39:617-622, 2002.
27. de Jong E, Mulder W, Nooitgedacht E, Taat CW, Bras J. Carney's triad. Eur J Surg Oncol 24:147-149, 1998.
28. Zak FG, Lawson W. The paraganglionic chemoreceptor system. Physiology, pathology and clinical medicine. New York: Springer Verlag, 1983.
29. Mulligan LM, Kwok JB, Healey CS, et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 363:458-460, 1993.
30. Takaya K, Yoshimasa T, Arai H, et al. Expression of the RET proto-oncogene in normal human tissues, pheochromocytomas, and other tumors of neural crest origin. J Mol Med 74:617-621, 1996.
31. Nakamura T, Ishizaka Y, Nagao M, Hara M, Ishikawa T. Expression of the ret proto-oncogene product in human normal and neoplastic tissues of neural crest origin. J Pathol 172:255-260, 1994.
32. Schuchardt A, D'Agati V, Larsson-Blomberg L, Costantini F, Pachnis V. Defects in the kidney and enteric nervous system of mice lacking the tyrosine kinase receptor Ret. Nature 367:380-383, 1994.
33. Takahashi M. The GDNF/RET signaling pathway and human diseases. Cytokine Growth Factor Rev 12:361-373, 2001.
34. Beldjord C, Desclaux-Arramond F, Raffin-Sanson M, et al. The RET protooncogene in sporadic pheochromocytomas: frequent MEN 2-like mutations and new molecular defects. J Clin Endocrinol Metab 80:2063-2068, 1995.
35. Eng C, Crossey PA, Mulligan LM, et al. Mutations in the RET proto-oncogene and the von Hippel-Lindau disease tumour suppressor gene in sporadic and syndromic phaeochromocytomas. J Med Genet 32: 934-937, 1995.
36. Woodward ER, Eng C, McMahon R, Voutilainen R, et al. Genetic predisposition to phaeochromocytoma: analysis of candidate genes GDNF, RET and VHL. Hum Mol Genet 6:1051-1056, 1997.
37. Rodien P, Jeunemaitre X, Dumont C, Beldjord C, Plouin PF. Genetic alterations of the RET proto-oncogene in familial and sporadic pheochromocytomas. Horm Res 47:263-268, 1997.
38. Marsh DJ, Zheng Z, Arnold A, et al. Mutation analysis of glial cell line-derived neurotrophic factor, a ligand for an RET/coreceptor complex, in multiple endocrine neoplasia type 2 and sporadic neuroendocrine tumors. J Clin Endocrinol Metab 82:3025-3028, 1997.
39. Lindor NM, Honchel R, Khosla S, Thibodeau SN. Mutations in the RET protooncogene in sporadic pheochromocytomas. J Clin Endocrinol Metab 80:627-629, 1995.
40. Komminoth P, Roth J, Muletta-Feurer S, Saremaslani P, Seelentag WK, Heitz PU. RET proto-oncogene point mutations in sporadic neuroendocrine tumors. J Clin Endocrinol Metab 81:2041-2046, 1996.
41. Dahia PL, Toledo SP, Mulligan LM, Maher ER, Grossman AB, Eng C. Mutation analysis of glial cell line-derived neurotrophic factor (GDNF), a ligand for the RET/GDNF receptor alpha complex, in sporadic phaeochromocytomas. Cancer Res 57:310-313, 1997.
42. van der Harst E, de Krijger RR, Bruining HA, et al. Prognostic value of RET proto-oncogene point mutations in malignant and benign, sporadic phaeochromocytomas. Int J Cancer 79:537-540, 1998.
43. Yoshimoto K, Tanaka C, Hamaguchi S, et al. Tumor-specific mutations in the tyrosine kinase domain of the RET proto-oncogene in pheochromocytomas of sporadic type. Endocr J 42:265-270, 1995.
44. Eng C, Smith DP, Mulligan LM, et al. Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours. Hum Mol Genet 3:237-241, 1994.
45. Le Hir H, Colucci-D'Amato LG, Charlet-Berguerand N, et al. High levels of tyrosine phosphorylated proto-ret in sporadic phenochromocytomas. Cancer Res 60: 1365-1370, 2000.
46. Edstrom E, Frisk T, Farnebo F, Hoog A, Backdahl M, Larsson C. Expression analysis of RET and the GDNF/GFRalpha-1 and NTN/GFRalpha-2 ligand complexes in pheochromocytomas and paragangliomas. Int J Mol Med 6:469-474, 2000.
47. . Matias-Guiu X, Colomer A, Mato E, et al. Expression of the ret proto-oncogene in phaeochromocytoma. An in situ hybridization and northern blot study. J Pathol 176:63-68, 1995.
48. de Krijger RR, van der Harst E, Muletta-Feurer S, et al. RET is expressed but not mutated in extra-adrenal paragangliomas. J Pathol 191:264-268, 2000.
49. Sims KB. Von Hippel-Lindau disease: gene to bedside. Curr Opin Neurol 14:695-703, 2001.
50. Stolle C, Glenn G, Zbar B, et al. Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene. Hum Mutat 12:417-423, 1998.
51. van der Harst E, de Krijger RR, Dinjens WN, et al. Germline mutations in the vhl gene in patients presenting with phaeochromocytomas. Int J Cancer 77:337-340, 1998.
52. Bar M, Friedman E, Jakobovitz O, et al. Sporadic phaeochromocytomas are rarely associated with germline mutations in the von Hippel-Lindau and RET genes. Clin Endocrinol (Oxf) 47:707-712, 1997.
53. Brauch H, Hoeppner W, Jahnig H, et al. Sporadic pheochromocytomas are rarely associated with germline mutations in the vhl tumor suppressor gene or the ret proto-oncogene. J Clin Endocrinol Metab 82:4101-4104, 1997.
54. Zbar B, Kishida T, Chen F, et al. Germline mutations in the Von Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan. Hum Mutat 8:348-357, 1996.
55. Chen F, Kishida T, Yao M, et al. Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: correlations with phenotype. Hum Mutat 5:66-75, 1995.
56. Gross DJ, Avishai N, Meiner V, Filon D, Zbar B, Abeliovich D. Familial pheochromocytoma associated with a novel mutation in the von Hippel-Lindau gene. J Clin Endocrinol Metab 81:147-149, 1996.
57. Dannenberg H, De Krijger RR, Van Der Harst E, et al. Von Hippel-Lindau gene alterations in sporadic benign and malignant pheochromocytomas. Int J Cancer 105:190-195, 2003.
58. Hofstra RM, Stelwagen T, Stulp RP, et al. Extensive mutation scanning of RET in sporadic medullary thyroid carcinoma and of RET and VHL in sporadic pheochromocytoma reveals involvement of these genes in only a minority of cases. J Clin Endocrinol Metab 81:2881-2884, 1996.
59. Bender BU, Gutsche M, Glasker S, et al. Differential genetic alterations in von Hippel-Lindau syndrome-associated and sporadic pheochromocytomas. J Clin Endocrinol Metab 85:4568-4574, 2000.
60. Los M, Jansen GH, Kaelin WG, Lips CJ, Blijham GH, Voest EE. Expression pattern of the von Hippel-Lindau protein in human tissues. Lab Invest 75:231-238, 1996.
61. Herman JG, Latif F, Weng Y, et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci USA 91:9700-9704, 1994.
62. Clifford SC, Prowse AH, Affara NA, Buys CH, Maher ER. Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis. Genes Chromosomes Cancer 22:200-209, 1998.
63. Ivan M, Kaelin WG, Jr. The von Hippel-Lindau tumor suppressor protein. Curr Opin Genet Dev 11:27-34, 2001.
64. Gnarra JR, Tory K, Weng Y, et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 7:85-90, 1994.
65. Turner KJ, Moore JW, Jones A, et al. Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation. Cancer Res 62:2957-2961, 2002.
66. Clifford SC, Cockman ME, Smallwood AC, et al. Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease. Hum Mol Genet 10:1029-1038, 2001.
67. Hoffman MA, Ohh M, Yang H, Klco JM, Ivan M, Kaelin WG, Jr. von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. Hum Mol Genet 10:1019-1027, 2001.
68. Zatyka M, da Silva NF, Clifford SC, et al. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease. Cancer Res 62:3803-3811, 2002.
69. Hergovich A, Lisztwan J, Barry R, Ballschmieter P, Krek W. Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL. Nat Cell Biol 5:64-70, 2003.
70. Airewele GE, Sigurdson AJ, Wiley KJ, et al. Neoplasms in neurofibromatosis 1 are related to gender but not to family history of cancer. Genet Epidemiol 20:75-86, 2001.
71. Friedman JM, Birch PH. Type 1 neurofibromatosis: a descriptive analysis of the disorder in 1,728 patients. Am J Med Genet 70:138-143, 1997.
72. Zoller ME, Rembeck B, Oden A, Samuelsson M, Angervall L. Malignant and benign tumors in patients with neurofibromatosis type 1 in a defined Swedish population. Cancer 79:2125-2131, 1997.
73. Walther MM, Herring J, Enquist E, Keiser HR, Linehan WM. von Recklinghausen's disease and pheochromocytomas. J Urol 162:1582-1586, 1999.
74. Gutmann DH, Geist RT, Rose K, Wallin G, Moley JE Loss of neurofibromatosis type I (NF1) gene expression in pheochromocytomas from patients without NF1. Genes Chromosomes Cancer 13:104-109, 1995.
75. Xu W, Mulligan LM, Ponder MA, et al. Loss of NF1 alleles in phaeochromocytomas from patients with type I neurofibromatosis. Genes Chromosomes Cancer 4:337-342, 1992.
76. Baysal BE, Ferrell RE, Willett-Brozick JE, et al. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science 287:848-851, 2000.
77. Baysal BE, Rubinstein WS, Taschner PE. Phenotypic dichotomy in mitochondrial complex II genetic disorders. J Mol Med 79:495-503, 2001.
78. Astuti D, Latif F, Dallol A, et al. Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am J Hum Genet 69:49-54, 2001.
79. Benn DE, Croxson MS, Tucker K, et al. Novel succinate dehydrogenase subunit B (SDHB) mutations in familial phaeochromocytomas and paragangliomas, but an absence of somatic SDHB mutations in sporadic phaeochromocytomas. Oncogene 22:1358-1364, 2003.
80. Cascon A, Cebrian A, Ruiz-Llorente S, Telleria D, Benitez J, Robledo M. SDHB mutation analysis in familial and sporadic phaeochromocytoma identifies a novel mutation. J Med Genet 39:E64, 2002.
81. Astuti D, Douglas F, Lennard TW, et al. Germline SDHD mutation in familial phaeochromocytoma. Lancet 357:1181-1182, 2001.
82. Gascon A, Ruiz-Llorente S, Cebrian A, et al. Identification of novel SDHD mutations in patients with phaeochromocytoma and/or paraganglioma. Eur J Hum Genet 10:457-461, 2002.
83. Bauters C, Vantyghem MC, Leteurtre E, et al. Hereditary phaeochromocytomas and paragangliomas: a study of five susceptibility genes. J Med Genet 40:E75, 2003.
84. Niemann S, Muller U, Engelhardt D, Lohse P. Autosomal dominant malignant and catecholamine-producing paraganglioma caused by a splice donor site mutation in SDHC. Hum Genet 113:92-94, 2003.
85. Niemann S, Muller U. Mutations in SDHC cause autosomal dominant paraganglioma, type 3. Nat Genet 26:268-270, 2000.
86. Gimenez-Roqueplo AP, Favier J, Rustin P, et al. Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas. Cancer Res 63:5615-5621, 2003.
87. Gimm O, Armanios M, Dziema H, Neumann HP, Eng C. Somatic and occult germline mutations in SDHD, a mitochondrial complex II gene, in nonfamilial pheochromocytoma. Cancer Res 60:6822-6825, 2000.
88. Aguiar RC, Cox G, Pomeroy SL, Dahia PL. Analysis of the SDHD gene, the susceptibility gene for familial paraganglioma syndrome (PGL1), in pheochromocytomas. J Clin Endocrinol Metab 86:2890-2894, 2001.
89. Kytola S, Nord B, Elder EE, et al. Alterations of the SDHD gene locus in midgut carcinoids, Merkel cell carcinomas, pheochromocytomas, and abdominal paragangliomas. Genes Chromosomes Cancer 34:325-332, 2002.
90. Perren A, Barghorn A, Schmid S, et al. Absence of somatic SDHD mutations in sporadic neuroendocrine tumors and detection of two germline variants in paraganglioma patients. Oncogene 21:7605-7608, 2002.
91. Ackrell BA. Progress in understanding structure-function relationships in respiratory chain complex II. FEBS Lett 466:1-5, 2000.
92. Hederstedt L. Structural biology. Complex II is complex too. Science 299:671-672, 2003.
93. Gimenez-Roqueplo AP, Favier J, Rustin P, et al. Functional consequences of a SDHB gene mutation in an apparently sporadic pheochromocytoma. J Clin Endocrinol Metab 87:4771-4774, 2002.
94. Gimenez-Roqueplo AP, Favier J, Rustin P, et al. The R22X mutation of the SDHD gene in hereditary paraganglioma abolishes the enzymatic activity of complex II in the mitochondrial respiratory chain and activates the hypoxia pathway. Am J Hum Genet 69:1186-1197, 2001.
95. Rodriguez-Cuevas S, Lopez-Garza J, Labastida-Almendaro S. Carotid body tumors in inhabitants of altitudes higher than 2000 meters above sea level. Head Neck 20:374-378, 1998.
96. Schulz N, Propst F, Rosenberg MP, et al. Pheochromocytomas and C-cell thyroid neoplasms in transgenic c-mos mice: a model for the human multiple endocrine neoplasia type 2 syndrome. Cancer Res 52:450-455, 1992.
97. Eng C, Foster KA, Healey CS, et al. Mutation analysis of the c-mos proto-oncogene and the endothelin-B receptor gene in medullary thyroid carcinoma and phaeochromocytoma. Br J Cancer 74:339-341, 1996.
98. Astuti D, Agathanggelou A, Honorio S, et al. RASSF1A promoter region CpG island hypermethylation in phaeochromocytomas and neuroblastoma tumours. Oncogene 20:7573-7577, 2001.
99. Aguiar RC, Dahia PL, Sill H, Toledo SP, Goldman JM, Cross NC. Deletion analysis of the p16 tumour suppressor gene in phaeochromocytomas. Clin Endocrinol (Oxf) 45:93-96, 1996.
100. Dackiw AP, Cote GJ, Fleming JB, et al. Screening for MEN1 mutations in patients with atypical endocrine neoplasia. Surgery 126:1097-1103; discussion 1103-1094, 1999.
101. Benn DE, Dwight T, Richardson AL, et al. Sporadic and familial pheochromocytomas are associated with loss of at least two discrete intervals on chromosome 1p. Cancer Res 60:7048-7051, 2000.
102. Mathew CG, Smith BA, Thorpe K, et al. Deletion of genes on chromosome 1 in endocrine neoplasia. Nature 328:524-526, 1987.
103. Tsutsumi M, Yokota J, Kakizoe T, Koiso K, Sugimura T, Terada M. Loss of heterozygosity on chromosomes 1p and 11p in sporadic pheochromocytoma. J Natl Cancer Inst 81:367-370, 1989.
104. Khosla S, Patel VM, Hay ID, et al. Loss of heterozygosity suggests multiple genetic alterations in pheochromocytomas and medullary thyroid carcinomas. J Clin Invest 87:1691-1699, 1991.
105. Moley JF, Brother MB, Fong CT, et al. Consistent association of 1p loss of heterozygosity with pheochromocytomas from patients with multiple endocrine neoplasia type 2 syndromes. Cancer Res 52:770-774, 1992.
106. Shin E, Fujita S, Takami K, et al. Deletion mapping of chromosome 1p and 22q in pheochromocytoma. Jpn J Cancer Res 84:402-408, 1993.
107. Vargas MP, Zhuang Z, Wang C, Vortmeyer A, Linehan WM, Merino MJ. Loss of heterozygosity on the short arm of chromosomes 1 and 3 in sporadic pheochromocytoma and extra-adrenal paraganglioma. Hum Pathol 28:411-415, 1997.
108. Herfarth KK, Wick MR, Marshall HN, Gartner E, Lum S, Moley JF. Absence of TP53 alterations in pheochromocytomas and medullary thyroid carcinomas. Genes Chromosomes Cancer 20:24-29, 1997.
109. Tanaka N, Nishisho I, Yamamoto M, et al. Loss of heterozygosity on the long arm of chromosome 22 in pheochromocytoma. Genes Chromosomes Cancer 5:399-403, 1992.
110. Tory K, Brauch H, Linehan M, et al. Specific genetic change in tumors associated with von Hippel-Lindau disease. J Natl Cancer Inst 81:1097-1101, 1989.
111. Yang KP, Nguyen CV, Castillo SG, Samaan NA. Deletion mapping on the distal third region of chromosome 1p in multiple endocrine neoplasia type IIA. Anticancer Res 10:527-533, 1990.
112. Devilee P, van Schothorst EM, Bardoel AF, et al. Allelotype of head and neck paragangliomas: allelic imbalance is confined to the long arm of chromosome 11, the site of the predisposing locus PGL. Genes Chromosomes Cancer 11:71-78, 1994.
113. van Schothorst EM, Beekman M, Torremans P, et al. Paragangliomas of the head and neck region show complete loss of heterozygosity at 11q22-q23 in chief cells and the flow-sorted DNA aneuploid fraction. Hum Pathol 29:1045-1049, 1998.
114. Wang DG, Barros D'Sa AA, Johnston CF, Buchanan KD. Oncogene expression in carotid body tumors. Cancer 77:2581-2587, 1996.
115. Wang DG, Johnston CF, Barros D'Sa AA, Buchanan KD. Expression of apoptosis-suppressing gene bcl-2 in human carotid body tumours. J Pathol 183:218-221, 1997.
116. Li SL, Goko H, Xu ZD, et al. Expression of insulin-like growth factor (IGF)-II in human prostate, breast, bladder, and paraganglioma tumors. Cell Tissue Res 291:469-479, 1998.
117. Jyung RW, LeClair EE, Bernat RA, et al. Expression of angiogenic growth factors in paragangliomas. Laryngoscope 110:161-167, 2000.
118. van Nederveen FH, Dannenberg H, Sleddens HF, de Krijger RR, Dinjens WN. p53 alterations and their relationship to SDHD mutations in parasympathetic paragangliomas. Mod Pathol 16:849-856, 2003.
119. Lin SR, Lee YJ, Tsai JH. Mutations of the p53 gene in human functional adrenal neoplasms. J Clin Endocrinol Metab 78:483-491, 1994.
120. Dahia PL, Aguiar RC, Tsanaclis AM, et al. Molecular and immunohistochemical analysis of P53 in phaeochromocytoma. Br J Cancer 72:1211-1213, 1995.
121. Reincke M, Wachenfeld C, Mora P, et al. p53 mutations in adrenal tumors: Caucasian patients do not show the exon 4 "hot spot" found in Taiwan. J Clin Endocrinol Metab 81:3636-3638, 1996.
122. Yoshimoto T, Naruse M, Zeng Z, et al. The relatively high frequency of p53 gene mutations in multiple and malignant phaeochromocytomas. J Endocrinol 159:247-255, 1998.
123. Lam KY, Lo CY, Wat NM, Luk JM, Lam KS. The clinicopathological features and importance of p53, Rb, and mdm2 expression in phaeochromocytomas and paragangliomas. J Clin Pathol 54:443-448, 2001.
124. Yana I, Nakamura T, Shin E, et al. Inactivation of the p53 gene is not required for tumorigenesis of medullary thyroid carcinoma or pheochromocytoma. Jpn J Cancer Res 83:1113-1116, 1992.
125. de Krijger RR, van der Harst E, van der Ham F, et al. Prognostic value of p53, bcl-2, and c-erbB-2 protein expression in phaeochromocytomas. J Pathol 188:51-55, 1999.
126. Gupta D, Shidham V, Holden J, Layfield L. Prognostic value of immunohistochemical expression of topoisomerase alpha II, MIB-1, p53, E-cadherin, retinoblastoma gene protein product, and HER-2/neu in adrenal and extra-adrenal pheochromocytomas. Appl Immunohistochem Mol Morphol 8:267-274, 2000.
127. Adleff V, Racz K, Toth M, Varga I, Bezzegh A, Glaz E. p53 protein and its messenger ribonucleic acid in human adrenal tumors. J Endocrinol Invest 21:753-757, 1998.
128. Hagemeyer O, Gabius HJ, Kayser K. Paraganglioma of the lung - developed after exposure to nuclear radiation by the Tschernobyl atomic reactor accident? Respiration 61:236-239, 1994.
129. Cheng L, Leibovich BC, Cheville JC, et al. Paraganglioma of the urinary bladder: can biologic potential be predicted? Cancer 88:844-852, 2000.
130. Wang DG, Johnston CF, Anderson N, Sloan JM, Buchanan KD. Overexpression of the tumour suppressor gene p53 is not implicated in neuroendocrine tumour carcinogenesis. J Pathol 175:397-401, 1995.
131. Guran S, Tali ET. p53 and p16INK4A mutations during the progression of glomus tumor. Pathol Oncol Res 5:41-45, 1999.
132. Moul JW, Bishoff JT, Theune SM, Chang EH. Absent ras gene mutations in human adrenal cortical neoplasms and pheochromocytomas. J Urol 149:1389-1394, 1993.
133. Moley JF, Brother MB, Wells SA, Spengler BA, Biedler JL, Brodeur GM. Low frequency of ras gene mutations in neuroblastomas, pheochromocytomas, and medullary thyroid cancers. Cancer Res 51:1596-1599, 1991.
134. Lin SR, Tsai JH, Yang YC, Lee SC. Mutations of K-ras oncogene in human adrenal tumours in Taiwan. Br J Cancer 77:1060-1065, 1998.
135. Pelengaris S, Khan M, Evan G. c-MYC: more than just a matter of life and death. Nat Rev Cancer 2:764-776, 2002.
136. Wang DG, Johnston CF, Marley JJ, et al. Expression of the apoptosis-suppressing gene BCL-2 in pheochromocytoma is associated with the expression of C-MYC. J Clin Endocrinol Metab 82:1949-1952, 1997.
137. Liu J, Voutilainen R, Kahri AI, Heikkila P. Expression patterns of the c-myc gene in adrenocortical tumors and pheochromocytomas. J Endocrinol 152:175-181, 1997.
138. Goto K, Ogo A, Yanase T, Haji M, Ohashi M, Nawata H. Expression of c-fos and c-myc proto-oncogenes in human adrenal pheochromocytomas. J Clin Endocrinol Metab 70:353-357, 1990.
139. Moley JF, Wallin GK, Brother MB, Kim M, Wells SA, Jr, Brodeur GM. Oncogene and growth factor expression in MEN 2 and related tumors. Henry Ford Hosp Med J 40:284-288, 1992.
140. Schwab M, Ellison J, Busch M, et al. Enhanced expression of the human gene N-myc consequent to amplification of DNA may contribute to malignant progression of neuroblastoma. Proc Natl Acad Sci USA 81:4940-4944, 1984.
141. Seeger RC, Brodeur GM, Sather H, et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 313:1111-1116, 1985.
142. Elder EE, Xu D, Hoog A, et al. KI-67 AND hTERT expression can aid in the distinction between malignant and benign pheochromocytoma and paraganglioma. Mod Pathol 16:246-255, 2003.
143. Hirano Y, Fujita K, Suzuki K, Ushiyama T, Ohtawara Y, Tsuda F. Telomerase activity as an indicator of potentially malignant adrenal tumors. Cancer 83:772-776, 1998.
144. Bamberger CM, Else T, Bamberger AM, et al. Telomerase activity in benign and malignant adrenal tumors. Exp Clin Endocrinol Diabetes 107:272-275, 1999.
145. Kubota Y, Nakada T, Sasagawa I, Yanai H, Itoh K. Elevated levels of telomerase activity in malignant pheochromocytoma. Cancer 82:176-179, 1998.
146. Lui WO, Chen J, Glasker S, et al. Selective loss of chromosome 11 in pheochromocytomas associated with the VHL syndrome. Oncogene 21:1117-1122, 2002.
147. Dannenberg H, de Krijger RR, Zhao J, et al. Differential loss of chromosome 11q in familial and sporadic parasympathetic paragangliomas detected by comparative genomic hybridization. Am J Pathol 158: 1937-1942, 2001.
148. Dannenberg H, Speel EJ, Zhao J, et al. Losses of chromosomes 1p and 3q are early genetic events in the development of sporadic pheochromocytomas. Am J Pathol 157:353-359, 2000.
149. Edstrom E, Mahlamaki E, Nord B, et al. Comparative genomic hybridization reveals frequent losses of chromosomes 1p and 3q in pheochromocytomas and abdominal paragangliomas, suggesting a common genetic etiology. Am J Pathol 156:651-659, 2000.
150. Kang Y, Siegel PM, Shu W, et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3:537-549, 2003.
151. Liotta LA, Kohn EC. Cancer's deadly signature. Nat Genet 33:10-11, 2003.
152. van 't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530-536, 2002.
153. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 100:57-70, 2000.
154. Amberson JB, Vaughan ED, Jr, Gray GF, Naus GJ. Flow cytometric determination of nuclear DNA content in benign adrenal pheochromocytomas. Urology 30:102-104, 1987.
155. Hosaka Y, Rainwater LM, Grant CS, Farrow GM, van Heerden JA, Lieber MM. Pheochromocytoma: nuclear deoxyribonucleic acid patterns studied by flow cytometry. Surgery 100:1003-1010, 1986.
156. Lai MK, Sun CF, Chen CS, Huang CC, Chu SH, Chuang CK. Deoxyribonucleic acid flow cytometric study in pheochromocytomas and its correlation with clinical parameters. Urology 44:185-188, 1994.
157. van der Harst E, de Herder WW, de Krijger RR, et al. The value of plasma markers for the clinical behaviour of phaeochromocytomas. Eur J Endocrinol 147:85-94, 2002.
158. Barshack I, Goldberg I, Nass D, Olchovsky D, Kopolovic J. CD44 expression in normal adrenal tissue and adrenal tumours. J Clin Pathol 51:52-54, 1998.
159. Bornstein SR, Ehrhart-Bornstein M, Gonzalez-Hernandez J, Schroder S, Scherbaum WA. Expression of interleukin-1 in human pheochromocytoma. J Endocrinol Invest 19:693-698, 1996.
160. Brown HM, Komorowski RA, Wilson SD, Demeure MJ, Zhu YR. Predicting metastasis of pheochromocytomas using DNA flow cytometry and immunohistochemical markers of cell proliferation: A positive correlation between MIB-1 staining and malignant tumor behavior. Cancer 86:1583-1589, 1999.
161. Castilla-Guerra L, Moreno AM, Fernandez-Moreno MC, Utrilla JC, Fernandez E, Galera-Davison H. Expression and prognostic value of c-erbB-2 oncogene product in human phaeochromocytomas. Histopathology 31:144-149, 1997.
162. Clarke MR, Weyant RJ, Watson CG, Carty SE. Prognostic markers in pheochromocytoma. Hum Pathol 29:522-526, 1998.
163. De Fraipont F, Le Moigne G, Defaye G, et al. Transcription profiling of benign and malignant adrenal tumors by cDNA macroarray analysis. Endocr Res 28:785-786, 2002.
164. Favier J, Plouin PF, Corvol P, Case JM. Angiogenesis and vascular architecture in pheochromocytomas: distinctive traits in malignant tumors. Am J Pathol 161:1235-1246, 2002.
165. Fogt F, Zimmerman RL, Mulligan N, et al. BCL-2 expression and inhibin-A in adrenal neoplasms: a comparative study. Int J Mol Med 3:271-274, 1999.
166. Furihata M, Ohtsuki Y. Immunohistochemical characterization of HLA-DR-antigen positive dendritic cells in phaeochromocytomas and paragangliomas as a prognostic marker. Virchows Arch A Pathol Anat Histopathol 418:33-39, 1991.
167. Glodny B, Winde G, Herwig R, et al. Clinical differences between benign and malignant pheochromocytomas. Endocr J 48:151-159, 2001.
168. Grouzmann E, Gicquel C, Plouin PF, Schlumberger M, Comoy E, Bohuon C. Neuropeptide Y and neuron-specific enolase levels in benign and malignant pheochro-mocytomas. Cancer 66:1833-1835, 1990.
169. Hoffman K, Gil J, Barba J, et al. Morphometric analysis of benign and malignant adrenal pheochromocytomas. Arch Pathol Lab Med 117:244-247, 1993.
170. Januszewicz W, Wocial B, Januszewicz A, Gryglas P, Prejbisz A. Dopamine and dopa urinary excretion in patients with pheochromocytoma - diagnostic implications. Blood Press 10:212-216, 2001.
171. Khorram-Manesh A, Ahlman H, Jansson S, Nilsson O. N-cadherin expression in adrenal tumors: upregulation in malignant pheochromocytoma and downregulation in adrenocortical carcinoma. Endocr Pathol 13:99-110, 2002.
172. Kinoshita H, Ogawa O, Mishina M, et al. Telomerase activity in adrenal cortical tumors and pheochromocytomas with reference to clinicopathologic features. Urol Res 26:29-32, 1998.
173. Koch CA, Vortmeyer AO, Diallo R, et al. Survivin: a novel neuroendocrine marker for pheochromocytoma. Eur J Endocrinol 146:381-388, 2002.
174. Kolomecki K, Stepien H, Bartos M, Kuzdak K. Usefulness of VEGF, MMP-2, MMP-3 and TIMP-2 serum level evaluation in patients with adrenal tumours. Endocr Regul 35:9-16, 2001.
175. Kumaki N, Kajiwara H, Kameyama K, et al. Prediction of malignant behavior of pheochromocytomas and paragangliomas using immunohistochemical techniques. Endocr Pathol 13:149-156, 2002.
176. Liu Q, Djuricin G, Staren ED, et al. Tumor angiogenesis in pheochromocytomas and paragangliomas. Surgery 120:938-942; discussion 942-933, 1996.
177. Masmiquel L, Castro-Forns M, de Torres I, Garcia A, Vidal MT, Simo R. Leu-M1 immunoreactiviry and phaeochromocytoma. J Clin Pathol 50:168-170, 1997.
178. Moreno AM, Castilla-Guerra L, Martinez-Torres MC, Torres-Olivera F, Fernandez E, Galera-Davidson H. Expression of neuropeptides and other neuroendocrine markers in human phaeochromocytomas. Neuropeptides 33:159-163, 1999.
179. Nagura S, Katoh R, Kawaoi A, Kobayashi M, Obara T, Omata K. Immunohistochemical estimations of growth activity to predict biological behavior of pheochromocytomas. Mod Pathol 12:1107-1111, 1999.
180. Nakada T, Kubota Y, Sasagawa I, Yagisawa T, Watanabe M, Ishigooka M. Remarkably suppressed manganese superoxide dismutase activity in malignant pheochromocytoma. J Urol 153:1787-1790, 1995.
181. Ohji H, Sasagawa I, Iciyanagi O, Suzuki Y, Nakada T. Tumour angiogenesis and Ki-67 expression in phaeochromocytoma. BJU Int 87:381-385, 2001.
182. Quiros RM, Kim AW, Maxhimer J, Gattuso P, Xu X, Prinz RA. Differential heparanase-1 expression in malignant and benign pheochromocytomas. J Surg Res 108:44-50, 2002.
183. Saeger W, Fassnacht M, Reincke M, Allolio B. Expression of HER-2/neu receptor protein in adrenal tumors. Pathol Res Pract 198:445-448, 2002.
184. Salmenkivi K, Arola J, Voutilainen R, et al. Inhibin/activin betaB-subunit expression in pheochromocytomas favors benign diagnosis. J Clin Endocrinol Metab 86:2231-2235, 2001.
185. Salmenkivi K, Haglund C, Arola J, Heikkila P. Increased expression of tenascin in pheochromocytomas correlates with malignancy. Am J Surg Pathol 25:1419-1423, 2001.
186. Salmenkivi K, Haglund C, Ristimaki A, Arola J, Heikkila P. Increased expression of cyclooxygenase-2 in malignant pheochromocytomas. J Clin Endocrinol Metab 86:5615-5619, 2001.
187. Schlumberger M, Gicquel C, Lumbroso J, et al. Malignant pheochromocytoma: clinical, biological, histologic and therapeutic data in a series of 20 patients with distant metastases. J Endocrinol Invest 15:631-642, 1992.
188. Stumvoll M, Fritsche A, Pickert A, Overkamp D. Features of malignancy in a benign pheochromocytoma. Horm Res 48:135-136, 1997.
189. Tormey WP, Fitzgerald RJ, Thomas G, Kay EW, Leader MB. Catecholamine secretion and ploidy in phaeochromocytoma. Int J Clin Pract 54:520-523, 2000.
190. Unger P, Hoffman K, Pertsemlidis D, Thung S, Wolfe D, Kaneko M. S100 protein-positive sustentacular cells in malignant and locally aggressive adrenal pheochromocytomas. Arch Pathol Lab Med 115:484-487, 1991.
191. van der Harst E, Bruining HA, Jaap Bonjer H, et al. Proliferative index in phaeochromocytomas: does it predict the occurrence of metastases? J Pathol 191:175-180, 2000.
192. Jacks T, Shih TS, Schmitt EM, Bronson RT, Bernards A, Weinberg RA. Tumour predisposition in mice heterozygous for a targeted mutation in Nf1. Nat Genet 7:353-361, 1994.
193. Smith-Hicks CL, Sizer KC, Powers JF, Tischler AS, Costantini F. C-cell hyperplasia, pheochromocytoma and sympathoadrenal malformation in a mouse model of multiple endocrine neoplasia type 2B. Embo J 19:612-622, 2000.
194. Kawai K, Iwashita T, Murakami H, et al. Tissue-specific carcinogenesis in transgenic mice expressing the RET proto-oncogene with a multiple endocrine neoplasia type 2A mutation. Cancer Res 60:5254-5260, 2000.
195. Crabtree JS, Scacheri PC, Ward JM, et al. A mouse model of multiple endocrine neoplasia, type 1, develops multiple endocrine tumors. Proc Natl Acad Sci USA 98:1118-1123, 2001.
196. Nikitin AY, Juarez-Perez MI, Li S, Huang L, Lee WH. RB-mediated suppression of spontaneous multiple neuroendocrine neoplasia and lung metastases in Rb+/- mice. Proc Natl Acad Sci USA 96:3916-3921, 1999.
197. Powers JF, Schelling K, Brachold JM, et al. High-level expression of receptor tyrosine kinase ret and responsiveness to ret-activating ligands in pheochromocytoma cell lines from neurofibromatosis knockout mice. Mol Cell Neurosci 20:382-389, 2002.
198. You MJ, Castrillon DH, Bastian BC, et al. Genetic analysis of Pten and Ink4a/Arf interactions in the suppression of tumorigenesis in mice. Proc Natl Acad Sci USA 99:1455-1460, 2002.
199. Pinkel D, Segraves R, Sudar D, et al. High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nat Genet 20:207-211, 1998.
200. Clark J, Edwards S, Feber A, et al. Genomewide screening for complete genetic loss in prostate cancer by comparative hybridization onto cDNA microarrays. Oncogene 22: 1247-1252, 2003.
201. Cai WW, Mao JH, Chow CW, Damani S, Balmain A, Bradley A. Genome-wide detection of chromosomal imbalances in tumors using BAG microarrays. Nat Biotechnol 20:393-396, 2002.
202. Albertson DG. Profiling breast cancer by array CGH. Breast Cancer Res Treat 78:289-298, 2003.
203. Asa SL, Ezzat S. The pathogenesis of pituitary tumours. Nat Rev Cancer 2:836-849, 2002.